AMENDMENTS TO THE SPECIFICATION

Docket No.: 251502007410

In the specification

On page 93, please amend the abstract beginning on line 4 as follows:

A compound according to formula (I) Compounds of the formula

wherein: © is <u>phenyl</u>, a <u>phenyl ring</u>, a C₄ to C₉ heteroaromatic, compound containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl or biphenyl group;

R¹, R² and R³ each independently represent a <u>are</u> hydrogen or halogen atom, or a hydroxyl group, or a phenyl, $-OR^4$, $-SR^4$, $-NR^4R^5$, $-NHCOR^4$, $-CONR^4R^5$, -CN, $-NO_2$, $-COOR^4$ or $-CF_3$ -group, or a straight or branched lower alkyl-group which may optionally be substituted, for example, with a hydroxyl or alcoxy group, wherein R⁴ and R⁵ each independently represent a hydrogen atom, straight or branched lower alkyl-group, or together form an alicyclic ring; or R⁴ and R² together form an aromatic, alicyclic or heterocyclic ring a substituent;

n is an integer from 0 to 4;


A represents a -CH₂-, -CH=CR⁶, -CR⁶=CH-, -CR⁶R⁷-, -CO-, -O-, -S-, -S(O)-, SO₂ or -NR⁶- group, wherein R⁶ and R⁷ each independently represent a are hydrogen or lower alkyl, atom, straight or branched lower alkyl group, or R⁶ and R⁷ together form an alicyclic ring;

m is an integer from 0 to 8; (when m = 0, A is not $-CH_2$ -); provided that when m = 0, A is not $-CH_2$ -;

p is 1 or 2 an integer from 1 to 2 and the substitution in the azonizbicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asymmetric carbons;

B represents a group of the formula -i) or ii):

wherein R¹⁰ represents a <u>is</u> hydrogen, <u>hydroxy</u> atom, a hydroxyl or methyl group; <u>and</u> and R⁸ and R⁹ each independently represents



wherein R¹¹-represents a hydrogen or halogen atom, or a straight or branched lower alkyl group and Q represents a single bond, -CH₂-, -CH₂-CH₂-, -O-, -O-CH₂-, -S-, -S-CH₂- or -CH=CH-, and when i) or ii) contain a chiral centre they may represent either configuration;

x represents an a pharmaceutically acceptable anion of a mono or polyvalent acid, and wherein the compounds show which shows high affinity for muscarinic M₃ receptors (Hm3).